334 related articles for article (PubMed ID: 32765484)
1. Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.
Romerio A; Peri F
Front Immunol; 2020; 11():1210. PubMed ID: 32765484
[TBL] [Abstract][Full Text] [Related]
2. Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives.
Zaffaroni L; Peri F
Future Med Chem; 2018 Feb; 10(4):461-476. PubMed ID: 29380635
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
Peri F; Piazza M
Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
5. Trehalose- and glucose-derived glycoamphiphiles: small-molecule and nanoparticle Toll-like receptor 4 (TLR4) modulators.
Rodriguez Lavado J; Sestito SE; Cighetti R; Aguilar Moncayo EM; Oblak A; Lainšček D; Jiménez Blanco JL; García Fernández JM; Ortiz Mellet C; Jerala R; Calabrese V; Peri F
J Med Chem; 2014 Nov; 57(21):9105-23. PubMed ID: 25268544
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule Modulators of Toll-like Receptors.
Wang Y; Zhang S; Li H; Wang H; Zhang T; Hutchinson MR; Yin H; Wang X
Acc Chem Res; 2020 May; 53(5):1046-1055. PubMed ID: 32233400
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.
Li J; Csakai A; Jin J; Zhang F; Yin H
ChemMedChem; 2016 Jan; 11(2):154-65. PubMed ID: 26136385
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and In Vivo Activity.
Facchini FA; Minotti A; Luraghi A; Romerio A; Gotri N; Matamoros-Recio A; Iannucci A; Palmer C; Wang G; Ingram R; Martin-Santamaria S; Pirianov G; De Andrea M; Valvano MA; Peri F
J Med Chem; 2021 Aug; 64(16):12261-12272. PubMed ID: 34382796
[TBL] [Abstract][Full Text] [Related]
9. Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.
Okamoto N; Mizote K; Honda H; Saeki A; Watanabe Y; Yamaguchi-Miyamoto T; Fukui R; Tanimura N; Motoi Y; Akashi-Takamura S; Kato T; Fujishita S; Kimura T; Ohto U; Shimizu T; Hirokawa T; Miyake K; Fukase K; Fujimoto Y; Nagai Y; Takatsu K
J Biol Chem; 2017 Sep; 292(37):15378-15394. PubMed ID: 28754693
[TBL] [Abstract][Full Text] [Related]
10. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
Reed SG; Hsu FC; Carter D; Orr MT
Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
[TBL] [Abstract][Full Text] [Related]
11. Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles.
Calabrese V; Cighetti R; Peri F
Mol Immunol; 2015 Feb; 63(2):153-61. PubMed ID: 24939379
[TBL] [Abstract][Full Text] [Related]
12. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
mBio; 2017 May; 8(3):. PubMed ID: 28487429
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of TLR4 for Inflammation, Infection, and Cancer: A Perspective for Disaccharide Lipid A Mimetics.
Heine H; Zamyatina A
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678520
[TBL] [Abstract][Full Text] [Related]
14. N-palmitoyl-D-glucosamine, a Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice.
Iannotta M; Belardo C; Trotta MC; Iannotti FA; Vitale RM; Maisto R; Boccella S; Infantino R; Ricciardi F; Mirto BF; Ferraraccio F; Panarese I; Amodeo P; Tunisi L; Cristino L; D'Amico M; Di Marzo V; Luongo L; Maione S; Guida F
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540826
[TBL] [Abstract][Full Text] [Related]
15. Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through induction of Tollip and negative regulation of IRAK-1.
Watts BA; Tamayo E; Sherwood ER; Good DW
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F705-F719. PubMed ID: 31241993
[TBL] [Abstract][Full Text] [Related]
16. Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.
Klett J; Reeves J; Oberhauser N; Pérez-Regidor L; Martín-Santamaria S
Curr Top Med Chem; 2014; 14(23):2672-83. PubMed ID: 25515751
[TBL] [Abstract][Full Text] [Related]
17. Insight Into TLR4-Mediated Immunomodulation in Normal Pregnancy and Related Disorders.
Firmal P; Shah VK; Chattopadhyay S
Front Immunol; 2020; 11():807. PubMed ID: 32508811
[TBL] [Abstract][Full Text] [Related]
18. TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.
Kuzmich NN; Sivak KV; Chubarev VN; Porozov YB; Savateeva-Lyubimova TN; Peri F
Vaccines (Basel); 2017 Oct; 5(4):. PubMed ID: 28976923
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
[TBL] [Abstract][Full Text] [Related]
20. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer.
Mishra V; Pathak C
Int J Biol Macromol; 2019 Feb; 122():425-451. PubMed ID: 30365988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
